浙江圣达生物药业股份有限公司2025年年度业绩预增公告

Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of the parent company between 50 million and 65 million yuan for the year 2025, representing an increase of 20.5755 million to 35.5755 million yuan compared to the previous year, which corresponds to a year-on-year growth of 69.93% to 120.90% [2][3] - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 43 million and 58 million yuan, indicating an increase of 20.5359 million to 35.5359 million yuan, with a year-on-year growth of 91.42% to 158.19% [2][3] Group 2: Previous Year Performance - In the previous year, the total profit was 49.0853 million yuan, with a net profit attributable to shareholders of the parent company at 29.4245 million yuan, and a net profit excluding non-recurring gains and losses at 22.4641 million yuan [5] Group 3: Reasons for Performance Increase - The increase in performance is attributed to the company's continuous promotion of refined management and technological upgrades, which have further optimized operational efficiency and cost structure. Additionally, the company has deepened its differentiated competition strategy and increased market expansion efforts, seizing market opportunities to enhance overall profitability [5] Group 4: Asset Impairment Provision - The company plans to recognize an asset impairment provision totaling approximately 9.15 million yuan for the year 2025, which includes a credit impairment loss of 0.65 million yuan and an asset impairment loss of 8.5 million yuan related to inventory [9][10] - The total impairment provision is expected to reduce the net profit attributable to shareholders of the listed company by 9.15 million yuan for the year 2025 [11]